Skip to Content




(kar bi DOE pa)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Lodosyn: 25 mg [scored; contains fd&c yellow #6 (sunset yellow)]

Generic: 25 mg

Brand Names: U.S.

  • Lodosyn

Pharmacologic Category

  • Anti-Parkinson Agent, Decarboxylase Inhibitor


Carbidopa is a peripheral decarboxylase inhibitor with little or no pharmacological activity when given alone in usual doses. It inhibits the peripheral decarboxylation of levodopa to dopamine; and as it does not cross the blood-brain barrier, unlike levodopa, effective brain concentrations of dopamine are produced with lower doses of levodopa. At the same time, reduced peripheral formation of dopamine reduces peripheral side-effects, notably nausea and vomiting, and cardiac arrhythmias, although the dyskinesias and adverse mental effects associated with levodopa therapy tend to develop earlier.


Does not cross the blood-brain barrier

Use: Labeled Indications

Given with carbidopa-levodopa in the treatment of parkinsonism to enable a lower dosage of levodopa to be used and a more rapid response to be obtained and to decrease side effects; use with carbidopa-levodopa in patients requiring additional carbidopa; has no effect without levodopa


Hypersensitivity to carbidopa or any component of the formulation; use of nonselective MAO inhibitor therapy with or within prior 14 days (however, may be administered concomitantly with the manufacturer's recommended dose of an MAO inhibitor with selectivity for MAO type B); narrow-angle glaucoma

Dosing: Adult

Parkinson's disease: Oral: Note: Optimal daily dosage determined by careful titration; generally if carbidopa is ≥70 mg/day, a 1:10 proportion of carbidopa:levodopa provides the most patient response.

Carbidopa augmentation in patients receiving carbidopa-levodopa:

Patients receiving Sinemet® 10/100: 25 mg carbidopa daily with first daily dose of Sinemet® 10/100; if necessary, 12.5-25 carbidopa mg may be given with each subsequent dose of Sinemet® 10/100; maximum: 200 mg carbidopa/day (including carbidopa from Sinemet®)

Patients receiving Sinemet® 25/250 or Sinemet® 25/100: 25 mg carbidopa with any dose of Sinemet® 25/250 or Sinemet® 25/100 throughout the day; maximum: 200 mg carbidopa/day (including carbidopa from Sinemet®)

Individual titration of carbidopa and levodopa: Initial: 25 mg carbidopa 3-4 times/day; administer at the same time as levodopa, initial dose of levodopa should be 20% to 25% of the previous levodopa dose in carbidopa-naive patients; first dose of carbidopa should be taken ≥12 hours after the last dose of levodopa in carbidopa-naive patients; increase or decrease dose by 1/2 or 1 tablet/day

Dosing: Geriatric

Refer to adult dosing.


Administer with meals to decrease GI upset.

Dietary Considerations

May be taken with meals to decrease GI upset.


Store at room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

Droxidopa: Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa. Monitor therapy

Test Interactions

False-positive reaction for urinary glucose with Clinitest®; false-negative reaction using Clinistix®; false-positive urine ketones with Acetest®, Ketostix®, Labstix®

Adverse Reactions

Adverse reactions are associated with concomitant administration with levodopa.

Cardiovascular: Cardiac arrhythmia, chest pain, edema, flushing, hypertension, hypotension, myocardial infarction, orthostatic hypotension, palpitation, phlebitis, syncope

Central nervous system: Abnormal dreams, abnormal gait, agitation, anxiety, ataxia, confusion, decreased mental acuity, delusions, dementia, depression (with or without suicidal tendencies), disorientation, dizziness, drowsiness, euphoria, extrapyramidal reaction, falling, fatigue, glossopyrosis, hallucination, headache, Horner's syndrome, impulse control disorder, insomnia, malaise, memory impairment, nervousness, neuroleptic malignant syndrome, nightmares, numbness, on-off phenomenon, paranoia, paresthesia, pathological gambling, peripheral neuropathy, psychosis, seizure (causal relationship not established), trismus

Dermatologic: Alopecia, bulla, diaphoresis, discoloration of sweat, skin rash

Endocrine & metabolic: Abnormal lactate dehydrogenase, glycosuria, hot flash, hyperglycemia, hypokalemia, increased libido (including hypersexuality), increased uric acid, weight changes

Gastrointestinal: Abdominal distress, abdominal pain, anorexia, bruxism, constipation, diarrhea, discoloration of saliva, duodenal ulcer, dysgeusia, dyspepsia, dysphagia, flatulence, gastrointestinal hemorrhage, heartburn, hiccups, nausea, sialorrhea, sore throat, vomiting, xerostomia

Genitourinary: Priapism, proteinuria, urinary frequency, urinary incontinence, urinary retention, urinary tract infection, urine discoloration

Hematologic & oncologic: Abnormal Coombs' test, agranulocytosis, anemia, decreased hematocrit, decreased hemoglobin, hemolytic anemia, leukopenia, malignant melanoma, thrombocytopenia

Hepatic: Abnormal alanine aminotransferase, abnormal alkaline phosphatase, abnormal aspartate transaminase, abnormal bilirubin levels, abnormal lactate dehydrogenase

Hypersensitivity: Angioedema, hypersensitivity reaction (bulla, IgA vasculitis, pruritus, urticaria)

Neuromuscular & skeletal: Back pain, dyskinesia (including choreiform, dystonic, and other involuntary movements), leg pain, muscle cramps, muscle twitching, shoulder pain, tremor, weakness

Ophthalmic: Blepharospasm, blurred vision, diplopia, mydriasis, oculogyric crisis (may be associated with acute dystonic reactions)

Renal: Increased blood urea nitrogen, increased serum creatinine

Respiratory: Cough, dyspnea, hoarseness, upper respiratory tract infection


Concerns related to adverse effects:

• Depression: Observe patients closely for development of depression with concomitant suicidal tendencies.

• Dyskinesias: May cause or exacerbate dyskinesias.

• Impulse control disorders: Antiparkinson therapy has been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), urges to spend money uncontrollably, and/or binge eating. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.

• Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.

• Psychotic effects: May cause hallucinations and psychotic-like behavior.

• Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs. Monitor for daytime somnolence or preexisting sleep disorder; caution with concomitant sedating medication; consider discontinuing if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).

Disease-related concerns:

• Psychotic disorders: Avoid use in patients with major psychotic disorder.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Other warnings/precautions:

• Appropriate use: Carbidopa has no antiparkinsonian activity when administered alone; must administer with carbidopa/levodopa. When administering to carbidopa-naive patients, administer carbidopa and carbidopa/levodopa at the same time; allow at least 12 hours to elapse between the last dose of carbidopa/levodopa and initiation of carbidopa.

• Discontinuation of therapy: Abrupt withdrawal or discontinuation of carbidopa/levodopa been associated with a syndrome resembling neuroleptic malignant syndrome (NMS).

Monitoring Parameters

Signs and symptoms of Parkinson's disease; CBC, liver function tests, renal function; blood pressure, mental status; signs and symptoms of neuroleptic malignant syndrome if abrupt discontinuation required (as with surgery); periodic intraocular pressure (in patients with wide-angle glaucoma); periodic skin examinations

Pregnancy Risk Factor


Pregnancy Considerations

Adverse events have not been observed in animal reproduction studies. Carbidopa can be detected in the umbilical cord but absorption in fetal tissue is minimal (Merchant, 1995). The incidence of Parkinson's disease in pregnancy is relatively rare and information related to the use of carbidopa in pregnant women is limited to use with other agents. Refer to the carbidopa and levodopa monograph for additional information.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience headache, dry mouth, fatigue, insomnia, change in taste, constipation, lack of appetite, or body fluid discoloration. Have patient report immediately to prescriber signs of depression (suicidal ideation, anxiety, emotional instability, or confusion); behavioral changes; hallucinations; uncontrollable urges; narcolepsy; severe nausea; severe vomiting; severe diarrhea; vomiting blood; black, tarry, or bloody stools; severe abdominal pain; burning or numbness feeling; bruising; bleeding; abnormal movements; twitching; change in balance; difficulty swallowing; difficulty speaking; severe dizziness; passing out; angina; chills; pharyngitis; skin growths; mole changes; vision changes; or signs of neuroleptic malignant syndrome (fever, muscle cramps or stiffness, dizziness, severe headache, confusion, change in thinking, tachycardia, abnormal heartbeat, or sweating a lot) (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.